Cathepsin B-Mediated Dysregulation of Autophagy Impairs Macrophage Function and Delays Healing in Diabetic Foot Ulcers

The human body possesses a remarkable, self-cleaning system that operates continuously at the microscopic level. Inside our cells, tiny recycling centers break down damaged parts and waste, ensuring the cell remains healthy and functional. This process, known as autophagy, is essential for the immune system's frontline defenders, the macrophages. These cells patrol the body, clearing away debris and fighting infection to allow wounds to heal. However, when the body is flooded with excess sugar, as seen in diabetes, this delicate recycling machinery can jam. The result is a failure to clear waste, leading to cell death and wounds that refuse to close. This is the reality for millions of people suffering from diabetic foot ulcers, a severe complication where a simple cut or sore on the foot can linger for months or years, often leading to amputation.

Researchers have long sought to understand why these wounds fail to heal, looking beyond the obvious issues of poor blood flow or infection. A team of scientists, led by Jia-Fu Xie and colleagues, recently turned their attention to a specific enzyme called cathepsin B. Think of this enzyme as a pair of molecular scissors that usually lives inside the cell's recycling center, helping to cut up old proteins. The team discovered that in the high-sugar environment of a diabetic foot, these scissors go into overdrive. Instead of helping the cell clean house, the excess activity of cathepsin B actually breaks the recycling system from the inside, causing the macrophages to malfunction and die. This discovery offers a new way to look at a stubborn medical problem, suggesting that the key to healing might lie in simply slowing down these overactive scissors.

To uncover this hidden mechanism, the researchers began by looking at the genetic blueprints of tissue samples. They analyzed data from thousands of genes, comparing healthy skin to skin from diabetic foot ulcers. By using advanced computer tools to sort through this massive amount of information, they identified a small group of genes that were both linked to the immune system and the cell's recycling process. Among these, the gene for cathepsin B stood out. It was significantly more active in the ulcer tissue than in healthy skin. To see exactly which cells were affected, the team then examined individual cells using a technique that reads the genetic code of single cells one by one. This high-resolution view confirmed that the overactive cathepsin B was concentrated specifically in the macrophages within the wound, the very cells responsible for cleaning up the injury site.

The team then moved from observation to experimentation to understand how this overactivity caused harm. They grew mouse macrophages in a laboratory dish and exposed them to high levels of sugar, mimicking the conditions inside a diabetic foot. Under normal conditions, these cells maintained a steady stream of recycling activity, visible as tiny, double-layered bubbles that carried waste to be destroyed. However, when the sugar levels were high, the cells began to change. The cathepsin B enzyme became overly abundant, and the recycling bubbles disappeared. The cells' internal power plants, the mitochondria, became swollen and damaged, and the cells began to produce toxic levels of reactive oxygen species, which are harmful molecules that damage cell structures. Ultimately, the cells started to die off. The researchers found that this was not just a random failure; the excess cathepsin B was actively suppressing a master switch inside the cell called TFEB. This switch normally tells the cell to build more recycling centers and keep the process running. By blocking this switch, the overactive enzyme effectively shut down the cell's ability to clean itself.

To test if stopping this enzyme could reverse the damage, the scientists introduced a specific chemical inhibitor, a substance designed to block cathepsin B, into the high-sugar cell cultures. The results were immediate and striking. When the enzyme was blocked, the master switch TFEB was able to move back into the cell's control center, and the recycling process began to work again. The toxic buildup of waste decreased, the power plants recovered, and the cells stopped dying. Encouraged by these results in the dish, the team took the next step and tested this approach in living animals. They created a model of diabetic foot ulcers in rats, a standard method for studying wound healing. One group of rats received the standard diabetic care, while another group received daily injections of the cathepsin B inhibitor.

The difference in healing was profound. The untreated diabetic rats struggled to close their wounds; after two weeks, the sores remained open, with inflamed and disorganized tissue underneath. In contrast, the rats treated with the inhibitor showed rapid improvement. Their wounds closed much faster, and by the end of the two-week period, the skin had healed over almost completely. When the researchers examined the tissue under a microscope, they saw that the treated wounds had a thicker, more organized layer of skin and far fewer signs of inflammation. The molecular markers confirmed that the cells in these healing wounds were once again capable of recycling their own waste and were no longer dying off at an accelerated rate. The treatment had successfully restored the natural healing cycle that diabetes had broken.

To ensure these findings were not limited to rats or mice, the team also examined tissue samples taken directly from human patients. They compared skin from healthy individuals to skin from patients with diabetic foot ulcers. The pattern held true: the human ulcer tissue showed high levels of cathepsin B, low levels of the recycling proteins, and high levels of cell death markers. This confirmed that the same biological breakdown observed in the lab and in animals was occurring in people. The study suggests that the persistent, non-healing nature of diabetic foot ulcers is driven by a specific chain reaction where high sugar triggers an enzyme to destroy the cell's cleaning system, leading to cell death and chronic inflammation.

The implications of this work are significant for how doctors might approach these difficult wounds in the future. Rather than just treating the symptoms of the wound, such as infection or lack of blood flow, this research points to a specific molecular target that could be addressed directly. By using drugs to inhibit cathepsin B, it may be possible to restart the cell's natural cleaning processes, allowing the immune cells to function correctly and the skin to heal. While the study was conducted in animals and cell cultures, and more research is needed to confirm safety and effectiveness in humans, the results provide a strong scientific foundation for a new type of treatment. It offers a clear path forward for turning a chronic, debilitating condition into a manageable one, giving hope that the body's own powerful healing mechanisms can be unlocked even in the face of diabetes.